Korean Drug Co. Ltd (014570) — Cash Flow-to-Debt Ratio
Korean Drug Co. Ltd (014570) has a Cash Flow-to-Debt Ratio of 0.27x as of September 2025, meaning its operating cash flow of ₩3.72 Billion could theoretically repay 0% of its total liabilities (₩14.01 Billion) in one year. See 014570 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Korean Drug Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Korean Drug Co. Ltd across 11 annual periods. Also explore Korean Drug Co. Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Korean Drug Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for Korean Drug Co. Ltd. For market capitalisation and broader financial context, see market cap of Korean Drug Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | ₩4.87 Billion | ₩10.78 Billion | ▲ +385.1% |
| 2023 | -0.16x | ₩-2.00 Billion | ₩12.62 Billion | ▼ -126.3% |
| 2022 | 0.60x | ₩5.91 Billion | ₩9.80 Billion | ▼ -18.3% |
| 2021 | 0.74x | ₩8.81 Billion | ₩11.92 Billion | ▼ -25.3% |
| 2020 | 0.99x | ₩12.33 Billion | ₩12.47 Billion | ▲ +71.9% |
| 2019 | 0.57x | ₩6.21 Billion | ₩10.80 Billion | ▲ +0.9% |
| 2018 | 0.57x | ₩5.79 Billion | ₩10.16 Billion | ▲ +1150.7% |
| 2017 | 0.05x | ₩447.20 Million | ₩9.82 Billion | ▼ -88.8% |
| 2016 | 0.41x | ₩3.96 Billion | ₩9.75 Billion | ▼ -36.9% |
| 2015 | 0.64x | ₩6.13 Billion | ₩9.52 Billion | ▲ +93.2% |
| 2014 | 0.33x | ₩4.46 Billion | ₩13.38 Billion | — |